Table 1.

The clinicopathological features of breast cancer patients.

Patient characteristics	Early stages BC patients (n = 80)	Late stages BC patients (n = 70)
Menopausal state
Premenopausal	33 (41.2)	25 (35.7)
Postmenopausal	47 (58.8)	45 (64.3)
First degree family history
Negative	75 (93.8)	65 (92.9)
Positive	5 (6.2)	5 (7.1)
Histological type of breast cancer
Duct carcinoma	80 (100)	30 (42.9)
Lobular carcinoma	0 (0.0)	23 (32.8)
Mixed duct and lobular	0 (0.0)	10 (14.3)
Poorly differentiated tumor	0 (0.0)	7 (10.0)
Biological type of breast cancer
Luminal A	43 (53.8)	27 (38.6)
Luminal B	3 (3.7)	7 (10.0)
Basal-like	34 (42.5)	18 (25.7)
HER2+	0 (0.0)	18 (25.7)
Tumor grade
GI	12 (15.0)	0 (0)
GII	65 (81.3)	30 (42.9)
GIII	3 (3.7)	40 (57.1)
Tumor stage
I	10 (12.5)	0 (0.0)
IIA	45 (56.2)	0 (0.0)
IIB	25 (31.3)	0 (0.0)
IIIA	0 (0.0)	32 (45.7)
IIIC	0 (0.0)	3 (4.3)
IV	0 (0.0)	35 (50)
Lymph node involvement
Negative	55 (68.8)
Positive	25 (31.2)	70 (100)
Estrogen receptors
Negative	33 (41.2)	36 (51.4)
Positive	47 (58.8)	34 (48.6)
Progesterone receptors
Negative	35 (43.7)	35 (50)
Positive	45 (56.3)	35 (50)
HER 2 expression
Score 0	77 (96.3)	45 (64.3)
Score 1	3 (3.7)	25 (35.7)
NPI
Good prognosis	37 (46.3)	0 (0.0)
Moderate prognosis	43 (53.7)	27 (38.6)
Poor prognosis	0 (0.0)	43 (61.4)
IHPI
Good prognosis	45 (56.3)	35 (50)
Moderate prognosis	35 (43.7)	17 (24.3)
Bad prognosis	0 (0.0)	18 (25.7)
Risk of recurrence
Intermediate	72 (90)	28 (40)
High	8 (10)	42 (60)

Values in parentheses indicate percentage; BC, breast cancer; n, number; HER2, human epidermal growth factor receptor 2; NPI, Nottingham prognostic index; IHPI, immunohistochemical prognostic index.